...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Thoracic Disease >Are there any ethnic differences in the efficacy and safety of immune checkpoint inhibitors for treatment of lung cancer?
【24h】

Are there any ethnic differences in the efficacy and safety of immune checkpoint inhibitors for treatment of lung cancer?

机译：免疫检查点抑制剂治疗肺癌的疗效和安全性是否有任何种族差异？

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Immunotherapy, especially immune checkpoint inhibitors, has revolutionized the treatment of non-small cell lung cancer. However, data on ethnic differences in response to these treatments are still lacking. We reviewed the currently available clinical data on immune checkpoint inhibitors and analyzed the ethnic difference in terms of treatment efficacies and side effects. Despite different epidemiology, genetic susceptibility and molecular profiles, Asian lung cancer patients demonstrated comparable outcomes to Western patients in terms of response rates and survival benefits. The incidence of immune-related adverse events has been reported with a higher incidence in Japanese patients, but was not consistent across other Asian patient populations, and warrants further investigation.
机译：免疫疗法，特别是免疫检查点抑制剂，已彻底改变了非小细胞肺癌的治疗。然而，仍然缺乏对这些治疗的族裔差异的数据仍然缺乏。我们在免疫检查点抑制剂上审查了目前可用的临床数据，并分析了治疗效率和副作用方面的民族差异。尽管流行病学不同，遗传易感性和分子型材，亚洲肺癌患者在反应率和生存效益方面向西方患者展示了可比的结果。据报道，日本患者的发病率较高，但在其他亚洲患者群体中均未符合免疫相关不良事件的发病率，并且不一致，并保证进一步调查。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号